Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 531 to 540 of 1090 total matches.
Extended-Release Trazodone (Oleptro) for Depression
The Medical Letter on Drugs and Therapeutics • Nov 15, 2010 (Issue 1351)
cannot be ruled out) for use in
pregnancy.
DRUG INTERACTIONS — CYP3A4 inhibitors ...
The FDA has approved the marketing of an
extended-release formulation of trazodone (Oleptro –
Angelini Labopharm) for treatment of major depressive
disorder in adults. Immediate-release trazodone
has been available for treatment of depression for
many years, but is used mostly in low doses for its
sedating effects.
Aliskiren/Amlodipine (Tekamlo): Another Combination Tablet for Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 29, 2010 (Issue 1352)
not be used during pregnancy.
DRUG INTERACTIONS — Aliskiren is metabolized by
CYP3A4 and P-glycoprotein (P ...
The FDA has approved Tekamlo (Novartis), an oral
fixed-dose combination of the direct renin inhibitor
aliskiren (Tekturna) and the calcium channel blocker
amlodipine (Norvasc, and others), for treatment of
hypertension in patients not adequately controlled on
monotherapy or already taking both drugs, and as initial
therapy in those likely to need multiple drugs to control
their blood pressure (BP). Both aliskiren and amlodipine
are available in combinations with other antihypertensive
agents.
Oral Propranolol (Hemangeol) for Infantile Hemangioma
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
hemangioma.
60
The Medical Letter ® Vol. 56 (1447) July 21, 2014
DRUG INTERACTIONS — Patients receiving ...
The FDA has approved an oral solution of the
nonselective beta-adrenergic blocker propranolol
(Hemangeol – Pierre Fabre) for treatment of proliferating
infantile hemangiomas.
Enfortumab Vedotin (Padcev) for Urothelial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 22, 2023 (Issue 1677)
these reactions
or who have other recurrent grade 3 or grade 4
skin reactions.
DRUG INTERACTIONS — Concomitant ...
Enfortumab vedotin-ejfv (Padcev – Astellas), a
nectin-4-directed antibody and microtubule inhibitor
conjugate, has received accelerated approval
from the FDA for use with the immune checkpoint
inhibitor pembrolizumab (Keytruda) for treatment
of locally advanced or metastatic urothelial cancer
in adults who are ineligible for cisplatin-containing
chemotherapy. Accelerated approval was based on
tumor response rates and the durability of response.
Med Lett Drugs Ther. 2023 May 22;65(1677):e91-2 doi:10.58347/tml.2023.1677g | Show Introduction Hide Introduction
Talquetamab (Talvey) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
should be monitored before starting
talquetamab and periodically thereafter.
DRUG INTERACTIONS ...
Talquetamab-tgvs (Talvey – Janssen), a bispecific
GPRC5D-directed T-cell engager, has been granted
accelerated approval by the FDA for treatment of
relapsed or refractory multiple myeloma in adults
who received ≥4 prior lines of therapy, including a
proteasome inhibitor, an immunomodulatory drug,
and an anti-CD38 monoclonal antibody. Accelerated
approval was based on the response rate and
durability of response. Talquetamab is the first
bispecific GPRC5D-directed T-cell engager to be
approved in the US
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e149-50 doi:10.58347/tml.2023.1684e | Show Introduction Hide Introduction
A Reminder: Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008 (Issue 1291)
Einstein College of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D ...
The U.S. Advisory Committee on Immunization Practices has recommended administration of the quadrivalent conjugated polysaccharide meningococcal vaccine (Menactra – Sanofi Pasteur) to all persons 11 to 18 years old, particularly those entering high school and college freshmen living in dormitories.1,2 The peak incidence of meningococcal disease, after early childhood, occurs in the 15-19 year-old age group. The conjugate vaccine is more immunogenic than the meningococcal capsular polysaccharide vaccine (Menommune – Sanofi Pasteur).ADVERSE EFFECTS — The most common adverse reactions with...
Guanfacine Extended-Release (Intuniv) for ADHD
The Medical Letter on Drugs and Therapeutics • Oct 18, 2010 (Issue 1349)
of Intuniv 1-mg
tablets costs $155.99.5
DRUG INTERACTIONS — Guanfacine is metabolized
primarily by hepatic ...
An extended-release oral formulation of guanfacine
hydrochloride (Intuniv – Shire), a selective alpha2A-adrenergic
agonist, has been approved by the FDA for
treatment of attention-deficit/hyperactivity disorder
(ADHD) in children 6-17 years old.
Testosterone Topical Solution (Axiron) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Jul 11, 2011 (Issue 1368)
testosterone
can unmask occult cancer in hypogonadal elderly
men.3
DRUG INTERACTIONS — Increased monitoring ...
The Medical Letter recently reviewed a topical gel formulation
of testosterone (Fortesta) for treatment of
hypogonadism in men. A topical testosterone replacement
product for application to the axilla, Axiron (Lilly)
solution, has now become available for the same indication.
This site of application presumably minimizes
the risk of transferring the drug to a family member or
sexual partner.
Sublingual Nitroglycerin Powder (GoNitro)
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
the tongue.
and paresthesia can occur with use of nitroglycerin
sublingual powder.
DRUG INTERACTIONS ...
The FDA has approved a sublingual powder formulation
of nitroglycerin (GoNitro – Espero) for prevention
or acute relief of an attack of angina pectoris. It
is the first powder formulation of nitroglycerin to
become available in the US. Most patients with
angina use sublingual nitroglycerin tablets (Nitrostat,
and generics). Translingual spray formulations of
nitroglycerin (NitroMist, Nitrolingual Pumpspray, and
generics) are also available.
Sotorasib (Lumakras) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
during treatment
with sotorasib and for 1 week after the last dose.
DRUG INTERACTIONS — The solubility ...
Sotorasib (Lumakras — Amgen), an oral KRAS
inhibitor, has received accelerated approval by the
FDA for treatment of KRAS G12C-mutated locally
advanced or metastatic non-small cell lung cancer
(NSCLC) in adults who received at least one prior
systemic therapy. Accelerated approval was based
on the overall response rate and duration of response.
KRAS mutations are found in 25-30% of non-squamous-cell NSCLC cases and the G12C mutation
is the most common KRAS mutation. Sotorasib is the
first KRAS inhibitor to be approved in the US.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e104-5 doi:10.58347/tml.2023.1678e | Show Introduction Hide Introduction